Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA-PREDICT: ctDNA to Predict Response in Early-Stage NSCLC
NCT06902272Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by University of Miami. Primary endpoints: Change in ctDNA Clearance: Neoadjuvant Phase at 3 months and Pathologic Complete Response at 3 months. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06902272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902272.